| Date Filed | Type | Description |
| 10/04/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 9,511 shares
@ $15.23, valued at
$144.9k
Sold 10,024 shares
@ $14.41, valued at
$144.4k
Sold 710 shares
@ $15.11, valued at
$10.7k
|
|
| 05/18/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 15,000 shares
@ $19.98, valued at
$299.7k
|
|
| 05/15/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 15,000 shares
@ $20.71, valued at
$310.7k
Sold 3,131 shares
@ $19.69, valued at
$61.6k
Sold 11,869 shares
@ $20.42, valued at
$242.4k
Sold 14,800 shares
@ $21.06, valued at
$311.7k
Sold 200 shares
@ $21.52, valued at
$4.3k
|
|
| 03/09/2023 |
4
| RATOFF STEVEN B (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 16,253 options to buy
@ $26, valued at
$422.6k
|
|
| 03/09/2023 |
4
| Graves Michael (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 16,253 options to buy
@ $26, valued at
$422.6k
|
|
| 03/09/2023 |
4
| Simpson Jennifer K. (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 16,253 options to buy
@ $26, valued at
$422.6k
|
|
| 03/09/2023 |
4
| Glenning Robert (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 16,253 options to buy
@ $26, valued at
$422.6k
|
|
| 03/09/2023 |
4
| Edlin Richard A. (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 16,253 options to buy
@ $26, valued at
$422.6k
|
|
| 03/09/2023 |
4
| BORIO LUCIANA (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 16,253 options to buy
@ $26, valued at
$422.6k
|
|
| 03/02/2023 |
4
| Cahill Brian Joseph (CFO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 718 shares
@ $28, valued at
$20.1k
Granted 18,500 shares
@ $0 |
|
| 03/02/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 3,113 shares
@ $28, valued at
$87.2k
Granted 70,900 shares
@ $0 |
|
| 02/06/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/24/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 3,732 shares
@ $33.64, valued at
$125.5k
|
|
| 01/09/2023 |
4
| Cahill Brian Joseph (CFO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 734 shares
@ $29.26, valued at
$21.5k
|
|
| 01/09/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 3,827 shares
@ $29.26, valued at
$112k
|
|
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/08/2022 |
4
| Edlin Richard A. (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 6,800 shares
@ $30.99, valued at
$210.7k
|
|
| 03/02/2022 |
4
| BORIO LUCIANA (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 11,200 options to buy
@ $47.39, valued at
$530.8k
|
|
| 03/02/2022 |
4
| Moran Michael Shawn (EVP, Chief Commercial Officer) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 10,400 shares
@ $0 |
|
| 03/02/2022 |
4
| Cahill Brian Joseph (CFO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 8,000 shares
@ $0 |
|
| 03/02/2022 |
4
| Edlin Richard A. (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 11,200 options to buy
@ $47.39, valued at
$530.8k
|
|
| 03/02/2022 |
4
| Simpson Jennifer K. (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 11,200 options to buy
@ $47.39, valued at
$530.8k
|
|
| 03/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/02/2022 |
4
| Graves Michael (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 11,200 options to buy
@ $47.39, valued at
$530.8k
|
|
| 03/02/2022 |
4
| Glenning Robert (Director) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 11,200 options to buy
@ $47.39, valued at
$530.8k
|
|
| 02/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2022 |
4
| Moran Michael Shawn (EVP, Chief Commercial Officer) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 210 shares
@ $45.94, valued at
$9.6k
|
|
| 02/01/2022 |
4
| Cahill Brian Joseph (CFO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 626 shares
@ $45.94, valued at
$28.8k
|
|
| 01/11/2022 |
4
| Moran Michael Shawn (EVP, Chief Commercial Officer) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 90 shares
@ $50.63, valued at
$4.6k
|
|
| 01/11/2022 |
4
| Cahill Brian Joseph (CFO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 263 shares
@ $50.63, valued at
$13.3k
|
|
| 01/07/2022 |
4
| Moran Michael Shawn (EVP, Chief Commercial Officer) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,511 shares
@ $50.69, valued at
$76.6k
|
|
|